AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score
By Verma A, Agarwal R, Anker SD et al.
Background: The prespecified FIDELITY analysis of two phase 3 trials found that finerenone reduced the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD); however, the magnitude of benefit in patients without prior CV disease (CVD) has not been characterized. The American Heart Association (AHA) Predicting Risk of cardiovascular disease EVENTs (PREVENT™) equations estimate 10-year CVD risk using a base model of clinical and hemodynamic characteristics and a full model that includes additional factors, such as the urinary albumin-to-creatinine ratio (UACR) and glycated hemoglobin, adapted to a T2D and CKD population. Research Question: Is the impact of finerenone on cardiovascular risk in patients with type 2 diabetes and chronic kidney disease, without a history of cardiovascular disease, influenced by the baseline PREVENT™ score? Does finerenone treatment mitigate the progression of the longitudinal score? Methods: In this post hoc analysis of the FIDELITY dataset, we stratified patients into tertiles of baseline PREVENT™ score (low/intermediate/high risk; base and full models) and calculated hazard ratios (HRs) using a Cox proportional hazards model for time to first non-fatal CV event. Treatment effect heterogeneity between tertiles was assessed via the interaction p -value. We calculated cumulative incidence and the number needed to treat (NNT) at 3 years for the time to first occurrence of a non-fatal CV event, based on Aalen-Johansen estimates. The change in PREVENT™ score up to Month 48 was analyzed using a linear mixed-effects model. Results: In total, 7050 patients without prior CVD were included (3519 finerenone; 3531 placebo). The effect of finerenone on non-fatal CV events was consistent across baseline PREVENT™ tertiles (Figure 1; base model low tertile HR [95% confidence interval] was 0.89 [0.60-1.32], intermediate 1.11 [0.79-1.56], high 0.85 [0.65-1.11]; p interaction 0.57 [base model] and 0.41 [full model]). Absolute benefit increased with baseline risk with lowest 3-year NNT seen in the high-risk tertile (28 patients, full model; Figure 2). Finerenone significantly reduced the progression of PREVENT™ score relative to placebo at Month 48 using the base model (least squares mean difference -0.018; p<0.01) and from Month 4 using the full model (p<0.0001; Figure 3). Conclusion: Finerenone demonstrated consistent CV benefit across AHA PREVENT™-estimated risk levels. The most significant absolute benefit and lowest NNT were observed in the highest risk tertile, supporting risk-based identification of individuals most likely to benefit. Finerenone also significantly decelerated longitudinal PREVENT™ score progression, with its greater effect in the comprehensive model including UACR supporting albuminuria reduction as a key mechanistic mediator of its disease modifying effects.